Trial Profile
A study evaluating predictive role of ribavirin plasma levels for sustained virologic response in difficult to treat hepatitis C-infected patients treated with direct-acting antivirals + ribavirin combination.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Jan 2017
Price :
$35
*
At a glance
- Drugs Daclatasvir/sofosbuvir (Primary) ; Ledipasvir/sofosbuvir (Primary) ; Peginterferon (Primary) ; Ribavirin (Primary) ; Simeprevir (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics; Therapeutic Use
- 31 Jan 2017 New trial record